Products

OsteoVue 653, deep-red fluorescent bone seeking probe

OsteoVue 653 is a deep-red fluorescent bone seeking probe that has a dendritic molecular architecture with a squaraine

rotaxane core scaffold and four peripheral iminodiacetate groups, which serve as the bone targeting units. OsteoVue 653

images areas of high bone turn over similarly to near infrared bisphosphonate probes [1] and may also image areas of

microcalcifications. It does not stain decalcified bone, which is strong evidence that the bone targeting is primarily due to

the Ca²⁺ chelation ability of the compound. Product contains 40 nmoles of OsteoVue 653 (2 x 20 nmole vials).

                              Fig. 1. Squaraine rotaxane based structure of OsteoVue 653.

Fig. 2. OsteoVue 653 abs (---), em (---) in water. Abs max=653 nm; Em max=677 nm. Log ε =5.15 and φ = 0.13

Fig. 3. Representative dorsal (A), leg (B), and chest (C) in vivo fluorescence images of skinless mice that have been treated

with probe 2 (OsteoVue 653) (4 nmol) via an intraperitoneal injection and OsteoSense750 (2 nmol) via a retro-orbital

injection. The images were acquired immediately after euthanization at 24 h pi of the probes and show fluorescence from

probe 2 (ex: 630/10 nm, em: 700/20 nm), fluorescence from OsteoSense750 (ex: 730/10 nm, em: 790/20 nm), and a

merged image (N = 3).

Applications

Useful for preclinical in vivo studies of bone growth or bone remodeling using optical imaging or in vivo fluorescence

guided surgery techniques. May enable in vivo detection of, measurement and monitoring of skeletal changes in a wide

variety of disease states, including arthritis, osteoporosis and cancer metastases. Useful for various in vitro bone binding

assays using microscopic or microarray detection systems.

Significant Advantages

(a) OsteoVue 653 provides a more stable signal in living mice over a 19 day period compared with OsteoSense750.

(b) Its intense narrow emission band allows OsteoVue 653 to be used in multiplex imaging protocols that employ several

     fluorescent probes when imaging bone growth.

(c) It is compatible with imaging systems equipped with standard Cy5 filter sets.

(d) Bisphosphonate probes like OsteoSense 750 can induce apoptosis in osteoclasts [2-4] whereas OsteoVue 653 does not

     [5].

References

[1] Harmatys, KM, Cole, EL, Smith, BD (2013). In Vivo Imaging of Bone Using a Deep-Red Fluorescent Molecular Probe

     Bearing Multiple Iminodiacetate Groups. Mol. Pharmaceutics, 10: 4263-4271.

[2] Russell RGG (2011). Bisphosphonates: the first 40 years. Bone, 49, 2-19

[3] Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects.

     Bone, 48, 677-92.

[4] Stern PH (2007). Antiresorptive agents and osteoclast apoptosis. J. Cell Biochem., 101, 1087-1096.

[5] Personal communication, Professor Bradley D Smith, University of Notre Dame.

Ordering information

▣ 관련 페이지 ; MTTI